	US 12,325,742 B2
	Anti-mesothelin antibodies
Jose Munoz-Olaya, Cambridge (GB); Remi Fertin, Cambridge (GB); Francisca Wollerton, Cambridge (GB); Mihriban Tuna, Cambridge (GB); and Neil Brewis, Cambridge (GB)
Assigned to INVOX PHARMA LIMITED, London (GB)
Appl. No. 17/259,677
Filed by INVOX PHARMA LIMITED, London (GB)
PCT Filed Jul. 12, 2019, PCT No. PCT/EP2019/068800 § 371(c)(1), (2) Date Jan. 12, 2021, PCT Pub. No. WO2020/011970, PCT Pub. Date Jan. 16, 2020.
Claims priority of application No. 1811415 (GB), filed on Jul. 12, 2018.
Prior Publication US 2022/0267421 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/18 (2013.01) [A61P 35/00 (2018.01); C07K 16/2878 (2013.01); G01N 33/57496 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. An antibody molecule that binds mesothelin (MSLN), wherein the antigen-binding site of the antibody molecule comprises the VH domain CDR1, CDR2 and CDR3 and the VL domain CDR1, CDR2 and CDR3 of antibody:

(i) FS28-256-271 set forth in SEQ ID NO: 98, 73, 99, 20, 21, and 44, respectively;

(ii) FS28-024-052 set forth in SEQ ID NO: 10, 11, 41, 20, 21 and 22, respectively;

(iii) FS28-256-021 set forth in SEQ ID NO: 98, 73, 99, 20, 21 and 34, respectively;

(iv) FS28-256-012 set forth in SEQ ID NO: 98, 73, 99, 20, 21 and 25, respectively;

(v) FS28-256-023 set forth in SEQ ID NO: 101, 73, 103, 20, 21 and 34, respectively;

(vi) FS28-256-024 set forth in SEQ ID NO: 98, 73, 99, 20, 21 and 43, respectively;

(vii) FS28-256-026 set forth in SEQ ID NO: 101, 73, 103, 20, 21 and 43, respectively;

(viii) FS28-256-027 set forth in SEQ ID NO: 98, 73, 99, 20, 21 and 44, respectively;

(ix) FS28-256-001 set forth in SEQ ID NO: 85, 73, 75, 20, 21 and 34, respectively;

(x) FS28-256-005 set forth in SEQ ID NO: 85, 73, 75, 20, 21 and 43, respectively;

(xi) FS28-256-014 set forth in SEQ ID NO: 111, 73, 113, 20, 21 and 25, respectively;

(xii) FS28-256-018 set forth in SEQ ID NO: 101, 73, 103, 20, 21 and 25, respectively;

(xiii) FS28-256 set forth in SEQ ID NO: 71, 73, 75, 20, 21 and 25, respectively;

(xiv) FS28-024-051 set forth in SEQ ID NO: 10, 11, 32, 20, 21 and 22, respectively;

(xv) FS28-024-053 set forth in SEQ ID NO: 10, 11, 51, 20, 21 and 22, respectively; or

(xvi) FS28-024 set forth in SEQ ID NO: 10, 11, 12, 20, 21 and 22, respectively; and

wherein the CDR sequences are defined according to the ImMunoGeneTics (IMGT) numbering scheme; and/or

wherein the antigen-binding site of the antibody molecule comprises the VH domain CDR1, CDR2 and CDR3 and the VL domain CDR1, CDR2 and CDR3 of antibody:

(i) FS28-256-271 set forth in SEQ ID NO: 97, 182, 100, 23, 24, and 44, respectively;

(ii) FS28-024-052 set forth in SEQ ID NO: 13, 14, 42, 23, 24 and 22, respectively;

(iii) FS28-256-021 set forth in SEQ ID NO: 97, 74, 100, 23, 24 and 34, respectively;

(iv) FS28-256-012 set forth in SEQ ID NO: 97, 74, 100, 23, 24 and 25, respectively;

(v) FS28-256-023 set forth in SEQ ID NO: 102, 74, 104, 23, 24 and 34, respectively;

(vi) FS28-256-024 set forth in SEQ ID NO: 97, 74, 100, 23, 24 and 43, respectively;

(vii) FS28-256-026 set forth in SEQ ID NO: 102, 74, 104, 23, 24 and 43, respectively;

(viii) FS28-256-027 set forth in SEQ ID NO: 97, 74, 100, 23, 24 and 44, respectively;

(ix) FS28-256-001 set forth in SEQ ID NO: 86, 74, 76, 23, 24 and 34, respectively;

(x) FS28-256-005 set forth in SEQ ID NO: 86, 74, 76, 23, 24 and 43, respectively;

(xi) FS28-256-014 set forth in SEQ ID NO: 112, 74, 114, 23, 24 and 25, respectively;

(xii) FS28-256-018 set forth in SEQ ID NO: 102, 74, 104, 23, 24 and 25, respectively;

(xiii) FS28-256 set forth in SEQ ID NO: 72, 74, 76, 23, 24 and 25, respectively;

(xiv) FS28-024-051 set forth in SEQ ID NO: 13, 14, 33, 23, 24 and 22, respectively;

(xiv) FS28-024-053 set forth in SEQ ID NO: 13, 14, 52, 23, 24 and 22, respectively; or

(xvi) FS28-024 set forth in SEQ ID NO: 13, 14, 15, 23, 24 and 22, respectively; and

wherein the CDR sequences are defined according to the Kabat numbering scheme; and

wherein the antibody molecule does not comprise a CD137 antigen-binding site located in a CH3 domain of the antibody molecule, said CD137 antigen-binding site comprising a first sequence as set forth in SEQ ID NO: 198 located in the AB structural loop of the CH3 domain and a second sequence as set forth in SEQ ID NO: 199 located in the EF structural loop of the CH3 domain.